Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$5.69
0.061.07%
At close: Jun 16, 5:00 PM EST
$5.69
N/A
After Hours: 4:00 PM EST
DiaMedica Therapeutics Inc Analyst Ratings
DMACNASDAQ
DiaMedica Therapeutics Analyst Ratings and Price Targets | NASDAQ:DMAC | Benzinga
DiaMedica Therapeutics Inc has a consensus price target of $12.67 based on the ratings of 6 analysts. The high is $25 issued by Cantor Fitzgerald on November 14, 2025. The low is $6 issued by Oppenheimer on August 16, 2024. The 3 most-recent analyst ratings were released by Cantor Fitzgerald, HC Wainwright & Co., and Craig-Hallum on November 14, 2025, August 15, 2025, and July 18, 2025, respectively. With an average price target of $16 between Cantor Fitzgerald, HC Wainwright & Co., and Craig-Hallum, there's an implied 181.20% upside for DiaMedica Therapeutics Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Cantor Fitzgerald
HC Wainwright & Co.
Craig-Hallum
Lake Street
Oppenheimer
1calculated from analyst ratings
Analyst Ratings for DiaMedica Therapeutics
Loading calendar...
FAQ
What is the target price for DiaMedica Therapeutics (DMAC) stock?
The latest price target for DiaMedica Therapeutics (NASDAQ:DMAC) was reported by Cantor Fitzgerald on November 14, 2025. The analyst firm set a price target for $25.00 expecting DMAC to rise to within 12 months (a possible 339.37% upside). 5 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for DiaMedica Therapeutics (DMAC)?
The latest analyst rating for DiaMedica Therapeutics (NASDAQ:DMAC) was provided by Cantor Fitzgerald, and DiaMedica Therapeutics initiated their overweight rating.
When was the last upgrade for DiaMedica Therapeutics (DMAC)?
The last upgrade for DiaMedica Therapeutics Inc happened on June 22, 2023 when Oppenheimer raised their price target to $7. Oppenheimer previously had a perform for DiaMedica Therapeutics Inc.
When was the last downgrade for DiaMedica Therapeutics (DMAC)?
There is no last downgrade for DiaMedica Therapeutics.
When is the next analyst rating going to be posted or updated for DiaMedica Therapeutics (DMAC)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of DiaMedica Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for DiaMedica Therapeutics was filed on November 14, 2025 so you should expect the next rating to be made available sometime around November 14, 2026.
Is the Analyst Rating DiaMedica Therapeutics (DMAC) correct?
While ratings are subjective and will change, the latest DiaMedica Therapeutics (DMAC) rating was a initiated with a price target of $0.00 to $25.00. The current price DiaMedica Therapeutics (DMAC) is trading at is $5.69, which is within the analyst’s predicted range.
